The Cigna Group
CI
$275.83
-2.37%
The Cigna Group is a diversified healthcare company operating primarily in the U.S., providing pharmacy benefit management (PBM) services through its Evernorth segment and health insurance products through Cigna Healthcare. Following its 2018 merger with Express Scripts, Cigna has become a major player in the PBM space, with its largest contract being with the Department of Defense and a recent multiyear deal with Centene. The company is currently undergoing a strategic review of its eviCore business and exiting the individual exchange market, signaling a shift toward core operations and higher-margin segments. Investors are focused on the company's ability to execute this strategic pivot while maintaining growth and profitability, as well as the potential impact of regulatory pressures on the healthcare sector.…
CI
The Cigna Group
$275.83
Related headlines
Investment Opinion: Should I buy CI Today?
Based on the data, Cigna is rated a Buy. The consensus recommendation is 'buy' with an average target price of $341.42, implying a 20.8% upside. The thesis is that the market is over-penalizing regulatory risks, creating a compelling value opportunity in a defensive healthcare franchise.
Sign up to view all
CI 12-Month Price Forecast
The AI assessment leans bullish given the compelling valuation and strong cash generation, but confidence is medium due to regulatory and execution risks. The stock's low beta and high free cash flow provide downside support, while the potential for EPS growth and strategic clarity could drive re-rating. To upgrade to high confidence, we would need evidence of regulatory clarity and sustained revenue acceleration above 6%. Conversely, a downgrade would occur if revenue growth falls below 3% or if regulatory actions materially impact margins.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cigna Group's 12-month outlook, with a consensus price target around $341.42 and implied upside of +23.8% versus the current price.
Average Target
$341.42
0 analysts
Implied Upside
+23.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$290 - $400
Analyst target range
The target price range spans from a low of $290.00 to a high of $400.00, with the high target implying a 41.6% upside, likely assuming successful execution of the strategic review and margin expansion. The low target is only 2.6% above the current price, suggesting that some analysts see limited upside due to potential headwinds such as regulatory pressures or competitive losses. The wide spread between low and high targets (38% difference) indicates high uncertainty about the company's future direction. Recent institutional ratings show a mix of actions, with some firms maintaining positive stances and others downgrading, reflecting the debate around Cigna's strategic pivot and its impact on near-term performance.
Drowning in data?
Find the real signal!
Bulls vs Bears: CI Investment Factors
Cigna presents a classic value-versus-value-trap debate. The bull case rests on a compelling valuation (forward PE 8.4x, PEG 0.15), robust EPS growth, and strong cash flow, while the bear case highlights decelerating revenue, thin margins, and regulatory risks. Currently, the evidence slightly favors the bulls given the low valuation and raised guidance, but the stock's inability to outperform the market over the past year signals lingering skepticism. The central tension is whether the strategic pivot to core operations can offset regulatory and competitive pressures, determining if the discount is an opportunity or a warning.
Bullish
- Deep value with forward PE of 8.4x: Cigna trades at a forward PE of 8.44x, a steep discount to the industry average of 22x. The PEG ratio of 0.15 suggests the market is pricing in minimal growth despite expected EPS expansion, offering a margin of safety for value investors.
- Strong EPS growth and raised guidance: Q1 2026 EPS surged to $6.30 from $4.88 a year ago, a 29% increase, and management raised full-year guidance. This demonstrates operational leverage and confidence in the core business, supporting the forward earnings estimates.
- Robust free cash flow generation: TTM free cash flow stands at $7.66 billion, providing ample capacity for debt reduction, share buybacks, and dividend growth. The payout ratio of 27% leaves room for future increases, enhancing shareholder returns.
- Low beta offers defensive characteristics: With a beta of 0.32, Cigna is significantly less volatile than the market, making it a defensive holding in turbulent times. This stability is attractive for risk-averse investors seeking healthcare exposure.
Bearish
- Revenue growth decelerating to 4.6%: Q1 2026 revenue grew only 4.57% YoY, down from 7.4% in Q4 2025 and 8.5% in Q3 2025. The sequential slowdown suggests fading momentum, which could pressure the premium valuation if it persists.
- Thin gross margin of 9.45%: Gross margin is only 9.45%, typical for PBMs but vulnerable to pricing pressure and regulatory changes. A small adverse shift in pharmacy costs could disproportionately impact profitability.
- Strategic review and market exit risks: The exit from the individual exchange market and the strategic review of eviCore introduce execution risk. These actions could lead to revenue loss or asset write-downs, creating near-term uncertainty.
- Regulatory overhang on PBM industry: As a major PBM, Cigna faces potential legislation aimed at curbing drug prices and PBM practices. Any adverse regulatory outcome could compress margins and limit growth, a key reason for the stock's discount.
CI Technical Analysis
Cigna's stock has been in a broad consolidation phase over the past year, with a 1-year price change of -7.08% and a current price of $282.52, which sits at approximately 43% of the 52-week range (between $239.51 low and $315.47 high). This positioning suggests the stock is trading closer to its lows, indicating a potential value opportunity but also reflecting investor caution. The stock's beta of 0.32 indicates it is significantly less volatile than the broader market, which may appeal to risk-averse investors but also limits upside participation in market rallies.
Beta
0.32
0.32x market volatility
Max Drawdown
-21.4%
Largest decline past year
52-Week Range
$240-$315
Price range past year
Annual Return
-8.3%
Cumulative gain past year
| Period | CI Return | S&P 500 |
|---|---|---|
| 1m | -2.4% | -0.9% |
| 3m | -6.8% | +5.6% |
| 6m | +3.7% | +15.0% |
| 1y | -8.3% | +18.1% |
| ytd | -1.2% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CI Fundamental Analysis
In the most recent quarter (Q1 2026), Cigna reported revenue of $68.49 billion, a 4.57% year-over-year increase, with revenue growth driven by both segments: Evernorth contributed $58.44 billion and Cigna Healthcare $11.48 billion. However, the growth rate has been decelerating from prior quarters, as Q4 2025 revenue was $72.47 billion, up from $65.60 billion in Q4 2024, but Q1 2025 revenue was $65.50 billion, indicating a sequential slowdown. Net income for Q1 2026 was $1.65 billion, with an EPS of $6.30, up from $1.32 billion in Q1 2025, reflecting improved profitability. Gross margin for the quarter was 9.45%, which is low but typical for the healthcare plans industry, and operating margin was 3.32%, showing slight improvement from the prior year's 3.01%.
Quarterly Revenue
$68.5B
2026-03
Revenue YoY Growth
+4.6%
YoY Comparison
Gross Margin
9.4%
Latest Quarter
Free Cash Flow
$7.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CI Overvalued?
Given that Cigna is profitable, the PE ratio is the primary valuation metric. The trailing PE is 12.34x, while the forward PE is 8.44x, indicating that the market expects significant earnings growth, which is supported by the PEG ratio of 0.15. Compared to the industry average PE of 22x (based on available data), Cigna trades at a substantial discount, which may reflect concerns about regulatory risks and the strategic review. Historically, Cigna's PE has ranged from around 7.6x to 32.7x over the past few years, with the current trailing PE near the lower end of that range, suggesting the stock is undervalued relative to its own history, but this could also indicate deteriorating fundamentals or a value trap.
PE
12.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.75, which is manageable but not negligible, and a current ratio of 0.85, indicating potential liquidity strain. The company's reliance on the PBM segment for the majority of revenue (85% in Q1) creates concentration risk, and the thin gross margin of 9.45% leaves little room for cost shocks. However, strong free cash flow of $7.66 billion TTM provides a buffer, and the payout ratio of 27% suggests dividend sustainability.
FAQ
The primary risks are regulatory, as PBM reforms could compress margins and reduce profitability. Competitive risks include losing contracts to rivals like CVS or UnitedHealth, which could impact revenue growth. Financial risks include a current ratio of 0.85, indicating potential liquidity issues, and a debt-to-equity ratio of 0.75, which is manageable but adds leverage. Execution risks from the strategic review of eviCore and the exit from individual exchanges could also lead to write-downs. The most severe risk is a combination of regulatory and competitive pressures leading to a re-rating to the 52-week low of $239.51.
The 12-month forecast is moderately bullish, with a base case probability of 50% targeting $310-$341, a bull case probability of 30% targeting $341-$400, and a bear case probability of 20% targeting $240-$290. The base case assumes steady growth and no major regulatory changes, leading to a re-rating toward the analyst average of $341. The bull case would require successful strategic execution and easing regulatory fears, while the bear case would involve adverse policy changes. Overall, the most likely scenario is a gradual appreciation toward the average target.
Cigna is undervalued relative to both its industry and its own history. The trailing PE of 12.34x is near the lower end of its historical range of 7.6x to 32.7x, and the forward PE of 8.44x is a steep discount to the industry average of 22x. The PEG ratio of 0.15 suggests the market is pricing in minimal growth, which seems overly pessimistic given the company's EPS growth of 29% in Q1 2026. The market appears to be discounting regulatory risks heavily, creating a potential value opportunity.
Cigna appears to be a good buy for value-oriented investors with a long-term horizon, given its forward PE of 8.44x versus the industry average of 22x and a PEG ratio of 0.15. The average analyst target of $341.42 implies a 20.8% upside, and the stock offers a 2.2% dividend yield. However, the main risk is regulatory pressure on PBM margins, which could limit upside. For investors comfortable with healthcare policy risk, the risk/reward is attractive at current levels.
Cigna is better suited for long-term investment due to its low beta of 0.32, which limits short-term trading opportunities, and its fundamental value proposition that may take time to be recognized. The stock has been range-bound over the past year, with a 1-year return of -7.08%, indicating a lack of momentum. However, for patient investors, the low valuation and strong cash flow could lead to significant upside over a 3-5 year horizon. A minimum holding period of 3 years is recommended to allow the strategic pivot and regulatory landscape to clarify.
